Investors & Media Press Releases

Press Releases

Summary Toggle

05.16.2019

Summary Toggle Axovant Announces Dosing of First Patient in Clinical Program for AXO-AAV-GM1, a Novel Gene Therapy for GM1 Gangliosidosis

Summary Toggle- Milestone marks the first patient with GM1 gangliosidosis treated with gene therapy- -Initial data expected in second half of 2019- -AXO-AAV-GM1 is Axovant’s third investigational gene therapy program to enter the clinic- BASEL, Switzerland , May 16, 2019 (GLOBE NEWSWIRE) -- Axovant Gene
Read More

PDF Version
Read More
Summary Toggle

05.07.2019

Summary Toggle Axovant Announces Reverse Share Split Effectiveness

Summary ToggleShares to begin trading on split-adjusted basis on May 8, 2019 BASEL, Switzerland , May 07, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that a reverse share split of its common shares on a
Read More

PDF Version
Read More
Summary Toggle

04.30.2019

Summary Toggle Axovant Announces Dosing of First Patient in Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD

Summary Toggle-Up to 6 patients to be enrolled in the second cohort, initial data expected in fourth quarter 2019- -Oral presentation at the Annual Meeting of the American Society of Gene and Cell Therapy - BASEL, Switzerland , April 30, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd.
Read More

PDF Version
Read More
Summary Toggle

04.16.2019

Summary Toggle Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

Summary Toggle-Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and the AXO-AAV-GM2 program to be featured in oral presentations- -Preclinical data from AXO-AAV-GM1 program to be highlighted in poster presentation- BASEL, Switzerland , April 16, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd.
Read More

PDF Version
Read More
Summary Toggle

04.04.2019

Summary Toggle Axovant Announces Plan to Effect Reverse Share Split

Summary Toggle- Closing of $40 million financing with participation from leading shareholders - - 1-for-8 reverse share split expected in May 2019 - BASEL, Switzerland , April 04, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies,
Read More

PDF Version
Read More
Summary Toggle

03.29.2019

Summary Toggle Axovant Announces Clinical Updates from AXO-AAV-GM2 and AXO-Lenti-PD Studies

Summary Toggle-R&D Day featuring leading physicians and scientists in Parkinson’s disease, GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs disease) will be webcast today at 8:30a.m. ET from New York - -Approximately 25% decrease in GM2 ganglioside in CSF observed at end of three-month period in the first
Read More

PDF Version
Read More
Summary Toggle

03.14.2019

Summary Toggle Axovant Sciences Announces Pricing of $40 Million Public Offering of Common Shares

Summary ToggleNEW YORK and BASEL, Switzerland , March 14, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 26,666,667 of its common shares at a price to the public of $1.50 per share.
Read More

PDF Version
Read More
Summary Toggle

03.13.2019

Summary Toggle Axovant Sciences Announces Public Offering of Common Shares

Summary ToggleNEW YORK and BASEL, Switzerland , March 13, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the common shares are being offered by Axovant.
Read More

PDF Version
Read More
Summary Toggle

03.11.2019

Summary Toggle Axovant Announces Clinical Update From First Tay-Sachs Disease Patient Dosed With AXO-AAV-GM2 Gene Therapy

Summary ToggleGenerally well-tolerated with no serious adverse events in a 30-month-old patient with advanced infantile Tay-Sachs disease Stable clinical condition from baseline to month 3 without deterioration on neurological exam Increase in CSF β-Hexosaminidase A enzyme activity from baseline to month 3,
Read More

PDF Version
Read More
Summary Toggle

03.11.2019

Summary Toggle Axovant Reports Positive Interim Results From First Cohort Of SUNRISE-PD Phase 2 Trial Of AXO-Lenti-PD Gene Therapy In Parkinson’s Disease

Summary Toggle25-point (42%) mean improvement in the UPDRS Part III (motor) OFF score, with individual patient improvements of 14-points and 36-points respectively Benefit seen across all UPDRS OFF subscales at 3 months Reductions in ON state dyskinesias seen on the Rush Dyskinesia Rating Scale and diary ON time
Read More

PDF Version
Read More

Investors & Media Press Releases

Press Releases

Email Alerts

Print

Email

Search

Investors & Media Press Releases

Press Releases

Toolbar

Email Alerts

Print

Email

Search